Happy to share this collaborative work with Cédric Le May on the benefit of empagliflozin on MASLD in a mice model of lipodystrophy. Congrats to Thibaud SOTIN and Sarra Smati for the nice work!
https://lnkd.in/eEjm8RBp
Our CEO Michelle Werner will be speaking at CureDuchenne's #FUTURES2024 on Friday about 'nonsense' mutations, which cause premature termination codons. Michelle will also speak about the unique potential of #tRNA medicines to treat #StopCodonDisease, especially in Duchenne muscular dystrophy. Given the unique challenges of dystrophin being one of the largest genes in the human genome, tRNA may be the only genetic medicine capable of rescuing the production of full-length dystrophin protein that has been truncated by a nonsense mutation.
Breakout Session: Therapeutics for Nonsense Mutations
🗓️ Friday, May 24
⌚ 3:30pm – 4:30pm EDT
📍Mediterranean Salon 8
See the full agenda here: https://lnkd.in/gGmkufeU#RNA#tRNAmedicines#tRNAbiology#geneticmedicines#rarediseases#raredisease#Duchenne#musculardystrophy
Sequence your cells and keep them alive. How? Cytosurge AG's FluidFM OMNIUM platform offers a gentle method for extracting a cytoplasmic biopsy, which can be sequenced using low-input or single-cell RNAseq protocols like Live-sequencing (Live-seq). This groundbreaking technique, recently published in Nature, shows that a cytoplasmic biopsy can accurately represent the transcriptome of a living cell.
Learn more about how to bring Live-seq to your lab during one of Cytosurge’s Lunch & Learn events coming up! https://bit.ly/3PtwbHL#NGS#scRNAseq#Liveseq#epigenetics#singlecell#genomics#cellbiology#AD
7-hmg has no traditional safe use data. 7-hmg has limited peer-reviewed preclinical research and the research that is available shows that 7-hmg does in fact have abuse potential and leads to respiratory depression, directly contradicting statements made by Jonathan Miller stating that 7-hmg has no abuse potential and no adverse effects.
The only research regarding the safety of 7-hmg shared in the policy announcement was in vitro cytotoxicity data, which is of little concern for 7-hmg and does not “prove” the safety of a compound. Mammalian models and clinical data must be used to determine the safety of a μ-opioid receptor agonist as a primary concern regarding its adverse effects are respiratory depression and dependence, which cannot be tested through in vitro models. Single-dose studies of 7-hmg have been delivered to beagles at a dose of 1 mg/kg orally which is equivalent to about 35 mg of 7-hmg in a 70 kg adult with no significant adverse effects. And a dose of 50 mg/kg 7-hmg was delivered to mice orally, which is the equivalent of about 285 mg of 7-hmg in a 70 kg adult and caused severe respiratory depression and seizures.
Kampmeyer stated that the availability of 7-hmg seems to have had a positive impact on consumers as a whole. This is not how safety and safe use data should be collected, by using individuals as guinea pigs to record their experience with a product. He further stated that they need to do their “due diligence” to ensure these compounds are safe, but the products are already on the market. No product should be on the market if its safety is not know – as was stated by the AKA earlier in the policy brief – a product must have a reasonable basis for safety in order to be on the market. 7-hmg needs to first be studied and its safety profile elucidated before any of these products should be made available to the public, instead the products are being made available and consumer experiences are being used as a tool to prove safety.
Henningfield stated regarding 7-hmg “its overall safety profile, its overall effect profile has not been studied nearly as well as mitragynine alone. And 7-hmg does raise greater concerns for scientists such as myself from an addiction and a safety perspective. This isn’t because there is a lot of evidence demonstrating it’s known harmful profile but it’s more the absence.” Dr Henningfield’s persistence that kratom should not contain 7-hmg clearly shows the concern over the use of 7-hmg.
kratom has been researched for a decade as a harm reduction tool, if 7-hmg had shown promise, researchers would have been pushing the compound forward in the drug approval process as an IND. This has not happened because the pharmacology and risk profile of the compound does not lend itself to being a alternative. 7-hmg is an opioid. So, it would not be an alternative to prescription but a replacement.
#AmericanKratomAssociationJosh Longhttps://lnkd.in/djaJdbfj
What do you know about genomics & heamoglobinopathies?
They're a group of inherited genetic conditions that include Sickle Cell Disease and Thalassaemia. Over 1,000 genetic mutations have been linked to this group.
Join our experts on March 20th from 1-2pm to learn more
https://bit.ly/HaemoLearn#thalassaemia#sicklecelldisease#ThinkGenomics#genetics
Excited to be on my way to the airport for ECTRIMS 2024. Looking forward to great sessions and talking to potential OCTOPUS collaborators. We’re planning an OCTOPUS industry engagement event for January 2025 - come and talk to one of the team Frederik BarkhofMarie BraisherClare WaltonMRC Clinical Trials Unit at UCL
A potential game changer in the field of AI, medicine and diagnostics in the making. It is so crucial that the power of AI is channelised towards creating a positive impact on the society. And this little start up may well be one to contribute to changing lives…
🌱 Introducing Silver Matter 🌱
Let us introduce you to Silver Matter 🧠 , a little seed that dreams big! We're just getting started in our cozy garage, with hopes and dreams reaching sky-high. We're all about making healthcare more affordable and accessible with our shiny new silver solutions.
Our mission? To make the detection of neurological diseases affordable, accessible, and accurate. We're combining cutting-edge tech with a sprinkle of creativity, a splash of teamwork and a vision to improve lives that will bring a silver lining to patient care around the globe. 🌍✨
Join us on this exciting journey and stay tuned for more! 🚀
Scientific Program Co-Chair Jose A. Carugno, MD, personally invites you to attend the 2nd World Summit on Hysteroscopy, March 8-9 in Ft. Lauderdale, FL. Watch the video, then make sure you register to secure your spot here https://bit.ly/480aDJC#AAGL#MIGS#GYNfluencers
Philip Li emphasizes the role of GA²LEN e.V. UCARE and ACARE network in the collaboration of scientists working on angioedema and shows how a dramatic increase in research for HAE occurred after the collaboration of many angioedema experts which translates into better care and development of new treatment options for angioedema. Thanks to the great efforts of Marcus Maurer and Markus Magerl. #angioedema